New Licensing Models For New Markets - BIO Conference
This article was originally published in PharmAsia News
CHICAGO - Whether or not the world is flat, licensing deals are no longer simply a transfer of global rights, and pharma companies are trying to determine how best to carve up regional rights and how to coordinate marketing efforts
You may also be interested in...
Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas
Roche plans to sign China-exclusive in-licensing deals with two Japanese pharma by the end of the year. The head-start of Roche and other western pharma has given them the capability and appetite for larger portfolios in key Asian markets.
SAN FRANCISCO - The number of large Western pharmaceutical companies is shrinking due to M&A activity, and outward-looking Japanese firms of all sizes are quickly becoming an attractive option for biotechs looking for global and regional deals